Gilead Sciences (GILD) stock

Infectious disease therapies , market cap $208B

Infectious disease therapies

Worth $208B

$170.87

+0.92%

FDA in 84 daysEvery upcoming FDA date ›

As of Tuesday's close · Live for Pro members at the open

Quality Score

Excellent

In its industry

#18of 281

Biotech

Checks firing

8of 14

Trending up

From 52-week high

-3.2%

under its best in a year

GILD's Quality Score was unchanged on Tue, Nov 10, at 16.

Follow GILD's trial news. Pro members can get an alert when Gilead Sciences files news, and see its trials, share raises, and its CEO's filings.

Get an alert when GILD files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextFeb 2, 2027 · In 84 days“…prophylaxis (“PrEP”), with a Prescription Drug User Fee Act target action date of February 2, 2027…”FDA decision date · SEC filing · Aug 4

Why is GILD up?

Up 3% on Oct 30, and still 2% over its Oct 29 close.

Its Oct 29 results: Biktarvy sales were $4.1B, up 10%; product gross margin was 81.0%, from 78.6% a year before. It rose 3% on Oct 30.

Sources: Price history, Oct 30, 2026; Company release, Oct 29, 2026

1 more reason, free with an account →1 more reason why GILD rose on Oct 30, from its filings, with the timeline and its peers, for Pro members.

Key facts on GILD

Key facts on GILD
Profit nearly doubled	$4.59B → $8.51B in 3 years
Latest filing	10-Q, Oct 30 Filed its quarterly report (10-Q) for the quarter to Sep 30, 2026

1 more reason behind GILD's 16, free with an account →3 more reasons behind GILD's 16, for Pro members.

GILD in the news

Fri Oct 30Gilead Sciences Announces Third Quarter 2026 Financial Results SEC filing 4:03 PM ET · Business Wire and 2 more GILD closed +3.1% that day.

What's next

Tue Nov 17: Jefferies 17th Annual London Global…Investor conference · date confirmed.

8 more dates ahead: conferences and dividend dates, for Pro members.

GILD catalysts

Coming up

After its last 4 reports it closed +1.1% on average, higher 2 of 4 times.

43 past catalysts since 2019, with sizes and sources, for Pro members.

What's next for GILD

Next step the company has named

Feb 2, 2027In 84 days“…300-mg tablets as a potential once-weekly oral formulation for HIV pre-exposure prophylaxis (“PrEP”), with a Prescription Drug User Fee Act target action date of February 2, 2027.”FDA decision date · SEC filing · Aug 4

What it means: the date by which the FDA has said it aims to decide on the company’s application. The FDA can decide earlier, or extend the date.

A trial underway: Asian Study of Sacituzumab Govitecan in HR+/HER2- Metastatic Breast CancerPhase 3 · Active · 331 people · main data estimated Dec 2026 · NCT04639986

72 more trials, 2 with data due this year, 23 drugs past Phase 1 and 30 filings, for Pro members.

Dilution on the horizon

Shelf registration (S-3ASR, filed Aug 6, 2026)
At-the-market share sales program (S-3ASR, filed Aug 6, 2026)

For Pro members: the amounts, and the share count against a year ago.

Insiders

An officer, Wettan Keeley M. Cain, sold 3,399 shares on Nov 6, under a planned sale. 36 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Daniel O'Day buys or sells

For Pro members: every trade, and Daniel O'Day’s 31 filings and quotes.

Get an alert before GILD's FDA date

A free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why GILD scores 16

Excellentfor quality, not price, 8 of 14 chart checks firingWhat the Quality Score means

+8Chart checks 8 of 14 firing right now, one point each
+4Long-term trend above a rising 200-⁠day average, near its 52-⁠week high, at a multi-⁠year high

Size adds
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Persistence adds

No effect today: Run-up, Dilution, Volatility, Cash flow, and News.

What every line is worth, and the reason behind it, on GILD and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 11:01 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when GILD's Quality Score turns up

A free account. No card.

How GILD ranks in Biotech

GILD is #18 of 281 by Quality Score.

How GILD ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	FULCFulcrum Therapeutics		Open for its score
	GENBGenerate Biomedicines		Open for its score
	GLUEMonte Rosa Therapeutics		Open for its score
	GPCRStructure Therapeutics		Open for its score
18	GILDGilead Sciences	8/14	16

Net income over four quarters: GILD -$3.86B, AMGN $9.39B, BIIB $348M, RVMD -$1.87B.

When does GILD report earnings, and what happens after?

Expected to report Tue Feb 9, after the close (in 91 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What GILD reported on Oct 29, 2026

The quarter

Sales of $8.3B, 7% more than a year ago; a profit of $1.94 a share, from $2.43.

“Total third quarter 2026 product sales increased 13% to $8.3 billion compared to the same period in 2025, primarily driven by higher sales of HIV products, Trodelvy® (sacituzumab govitecan-hziy) and Livdelzi® (seladelpar), partially offset by lower sales of Veklury® (remdesivir) and Cell Therapy products.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

Where the quarter's sales came from
Line	Q3 2026	Q2 2026	Q3 2025
By product
Productup 13%	$8.3B33%	$7.6B33%	$7.3B32%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Oct 30)

26 more lines, for Pro members.

The outlook

The outlook the company gave, by period
Measure	Figure
Full year 2026
Product sales	$ 31,000 $ 31,300raised

Figures as filed (SEC filing, Oct 29)

In the company's words

“The decrease was primarily driven by net losses from equity securities in the current year compared to net gains in the prior year, higher operating expenses, higher income tax expense and lower royalty, contract and other revenues, partially offset by higher product sales and lower acquired in-process research and development (“IPR&D”) expenses.”

From its results filing (SEC filing · Oct 29)

The numbers

Market value: $208B; today
Sales: $31B; up 6.5% on the year
Free cash flow: $14B; last 12 months

Sales grew 3.6% a year over 5 years, fiscal 2020 to 2025.

Pays $3.28 a share a year.

5 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on GILD: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-2.0%-2.6%+3.1%

May 7Aug 4Oct 29

Reported	When	Gap	Reaction	5 days
Oct 29, 2026After close	After close	+2.8%	+3.1%	+1.2%
Aug 4, 2026After close	After close	+0.6%	-2.6%	+0.4%
May 7, 2026After close	After close	-3.0%	-2.0%	-1.5%

GILD closed higher after 2 of its last 4 reports.

All 4 reports, and GILD's Quality Score going into each

GILD sales and profit by year

Sales and profit by year

Sales grew in five of the last seven years, to $29B in 2025. It made a profit in each of the eight years.

GILD has 8 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on GILD, and all 14 on every stock.Get in free →

GILD RSI today: 64.2, above its 50-day and 200-day averages

Not scored

RSI 64.2, MACD above signal, above both averages. Not scored.13 readings

The deep dive on GILD

What it does and how it makes money4 findings"We also generate revenues from other activities, including royalties for outbound licenses of our intellectual property, sales of certain intellectual property and other payments received from our collaborations with third-party partners." (10-K for fiscal 2025)SEC filing · Feb 24, 2026
Where it stands4 findingsFor Pro members4 findings on where GILD stands: its cash, debt, and share count, for Pro members
What changed in its filings4 findings"In August 2026, we filed another lawsuit against Cipla in the U.S. District Court for the District of Delaware, which was subsequently consolidated with the Descovy 505(b)(2) litigation." (10-Q for the quarter to Sep 30, 2026)SEC filing · Oct 30, 2026A new heading in its "Risk Factors" this year: "Our U.S. manufacturing and R&D investments may not achieve their intended benefits and could adversely affect our business, results of operations and cash flows." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 24, 2026, against the one of Feb 28, 2025
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades GILD, for Pro members
Against its closest peers3 peersNet income over four quarters: GILD -$3.86B, AMGN $9.39B, BIIB $348M, RVMD -$1.87B.

12 more findings on GILD, each with its source, for Pro members.

GILD share count over time

Shares: about the same count as a year ago (to Sep 30).

Shares of GILD outstanding, as filed
Shares outstanding	As of
1.24B	Oct 23, 2026
1.24B	Jul 31, 2026
1.24B	Apr 30, 2026
1.24B	Feb 13, 2026

Offerings, shelves, and splits of GILD, from its filings
From its filings	Filed
Registered shares for a later sale (S-3ASR)	Aug 6, 2026

Is GILD's dividend covered? What its financials say

Its dividends come to 30% of its free cash flow.

GILD's dividend against its free cash flow
Dividend	$3.28 a share a year Paid 4 times a year
Paid out	About $4.1B a year $3.28 a share on 1.3B shares, its average count in the quarter to Sep 30, 2026
Free cash flow	$14B The last four quarters, to Sep 30, 2026
Record	Raised every year since 2015 Its dividends a share each year, from its annual reports

GILD insider trades

GILD trades by Congress and the executive branch

18 trades disclosed in the last six months. The newest:

SellDonald Trump$1K to $15KPresident (R)traded Jul 24, disclosed Sep 22(60 days later)

SellDonald TrumpPresident (R)$1K to $15Ktraded Jul 24, disclosed Sep 22(60 days later)

All 18 trades on GILD disclosed by Congress and the executive branch, for Pro members.Get in free →

See what Congress is buying across the market

GILD's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Daniel Patrick O'DayChairman & CEO · 17 trades
Andrew D. DickinsonChief Financial Officer · 12 trades
Johanna MercierChief Comm & Corp Aff Officer · 12 trades
Deborah H. TelmanEVP, Corporate Affairs & GC · 1 trade
Wettan Keeley M. CainEVP Gen Counsel, Legal & Comp · 1 trade
Dietmar BergerChief Medical Officer · no trades on file
Erin BurkhartSVP, Controllership · no trades on file
Jeffrey BluestoneDirector · 3 trades

7 more officers and directors file at GILD.

See insider trades by person

Which ETFs hold GILD?

In ETFs: GILD is 1.2% of SPMO, 1.1% of DGRO, and 1.0% of QQQI, the most of the 24 funds Breakaway covers, by each fund's latest filing, Jun 30 to Aug 31, 2026.

About Gilead Sciences

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

17,000 employeesFoster City, CAgilead.com

What Gilead Sciences says it competes with

“We operate in a highly competitive environment.”

From its annual report, SEC filing · Feb 24, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on GILD and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would move GILD's score: 4 things
3 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawaySep 22Donald Trump bought GILD$15K to $50K, disclosed Sep 22

Alerts are optional.

See GILD's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: GILD's Quality Score is 16 (Excellent), #18 of 281 in Biotech.

What does GILD's Quality Score say?

GILD scores 16 today, which Breakaway calls Excellent. It is #18 of 281 in Biotech by Quality Score, with 8 of 14 chart checks firing. Up 3% on Oct 30, and still 2% over its Oct 29 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is GILD's Quality Score?

GILD scores 16 today, which Breakaway calls Excellent (15 to 19). That is #18 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind GILD's 16.

When does GILD report earnings?

Expected to report Tue Feb 9, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. GILD closed higher after 2 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.